v3.26.1
COMMITMENTS AND CONTINGENCIES - Narrative (Details)
$ in Millions
3 Months Ended
Mar. 31, 2026
USD ($)
Loss Contingencies [Line Items]  
Purchase obligation $ 6.5
Takeda Pharmaceuticals U.S.A., Inc.  
Loss Contingencies [Line Items]  
Licenses agreement, planned stockholder distribution from proceeds, percentage 25.00%